<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01555294</url>
  </required_header>
  <id_info>
    <org_study_id>CMO 2003/174</org_study_id>
    <nct_id>NCT01555294</nct_id>
  </id_info>
  <brief_title>Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification</brief_title>
  <acronym>NIMA</acronym>
  <official_title>Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification: a Study in a Population-based Cohort and Familial Combined Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple risk factors contribute to atherosclerosis, which ultimately results in clinical
      manifestation of cardiovascular disease. Atherosclerosis results in both functional and
      morphological changes in the vessel wall, which can be measured by ultrasonography. The
      current study has been designed to

        1. To evaluate whether non-invasive measurements of atherosclerosis are independent
           predictors of cardiovascular disease and

        2. to delineate new biochemical parameters and genetic variations, allowing earlier and
           more effective preventive therapy

        3. The investigators intend to set guidelines for use of NIMA in an outpatient setting to
           facilitate early detection of increased cardiovascular risk and monitor life-style and
           pharmaceutical interventions.

      In both the general population and in Familial Combined Hyperlipidemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular disease (CVD) is the major cause of death in all developed countries.
      Atherosclerosis is the main cause of CVD. Abundant evidence indicates the 4 major independent
      risk factors for atherosclerosis and CVD include cigarette smoking, elevated blood pressure,
      elevated total cholesterol and diabetes mellitus. However, a major problem in clinical
      medicine is that at every level of risk factor exposure, there is a large inter-individual
      variation in the amount of atherosclerosis and the development of CVD. Therefore, it is
      difficult to predict the CVD risk in an individual patient based on risk factor screening
      alone.

      Non-invasive measurements of atherosclerosis (NIMA): An indicator of the overall effect of
      all known and unknown potential risk factors for atherosclerosis in vivo can be assessed by
      measuring atherosclerosis directly in the vessel wall. This also provides the opportunity to
      measure atherosclerosis before developing symptoms of CVD, as changes in the arterial wall
      precede clinical symptoms of CVD.

      Objectives: (1)The main objective is to evaluate whether NIMA are independent predictors of
      CVD and thus add information to traditional risk factor stratification. (2) Furthermore, we
      will delineate new biochemical and genetic risk factors, allowing earlier and more effective
      preventive therapy. (3) We intend to set guidelines for use of NIMA in an outpatient setting
      to facilitate early detection of increased cardiovascular risk and monitor life-style and
      pharmaceutical interventions.

      We will evaluate 4 different NIMA, based on ultrasound and tonometry techniques, including
      intima media thickness (IMT), endothelial function by flow mediated dilation (FMD),
      ankle-brachial index (ABI), Pulse Wave Analyses(PWA) and pulse wave velocity (PWV). The power
      of NIMA, to predict cardiovascular events will be studied in two available populations, a low
      risk population cohort, the Nijmegen Biomedical Study (NBS) and a high risk population,
      families with Familial Combined Hyperlipidemia.

      The NBS is a prospective population survey aimed at investigating the frequency of genetic
      variations in the general population. The study population is recruited as a sex- and
      age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000).
      Recruitment has started in October 2001. The present study is a substudy in the NBS. A
      follow-up approach will be used to evaluate whether NIMA are related to future cardiovascular
      events. In total 1517 participants aged 50-70 years were included.

      FCH is the most common inherited hyperlipidemia in man. Affected individuals are
      characterized by elevated cholesterol and/or triglyceride levels and other associated traits
      including small-dense LDL, insulin resistance, oxidative stress and increased apoB levels,
      which have been proposed to contribute to the increased risk of CVD. So, this population will
      be most informative to evaluate the relevance of NIMA in CVD risk assessment as patients
      exhibit numerous, additive risk factors, which are missed in traditional cardiovascular risk
      assessment. Our data base contains a unique population of 40 well-characterized FCH families,
      including 687 patients, relatives and spouses with 5 years follow-up data. These families
      participate in an ongoing long-term follow-up program with registration of CVD.

      All four NIMA's, including IMT, ABI, PWV/PWA, FMD, and both traditional and new biochemical
      and genetic parameters will be measured in both populations. The relevance of NIMA in
      identifying subjects at increased risk of CVD will be determined. Furthermore, the effect of
      risk factors on IMT, ABI, PWV and FMD will be studied, including clinical and traditional
      risk factors and new biochemical parameters and genetic variations.

      Innovative aspects: We will develop an evidence based protocol for NIMA to show the presence
      of atherosclerosis before clinical manifestation of CVD and to improve cardiovascular risk
      stratification beyond traditional risk factor screening. Furthermore, we will delineate new
      risk factors, including both biochemical parameters and genetic variations, contributing to
      design optimal (new) treatment and to develop new strategies for prevention of CVD in the
      general population and in a high risk population, FCH.

      Clinical relevance: If NIMA turns out to provide powerful information in identifying subjects
      at increased risk of CVD we will incorporate NIMA into clinical practice guidelines for the
      purpose of cardiovascular risk stratification and evaluation of risk management strategies.
      The identification of potential new biochemical and/or genetic risk factors will be very
      helpful to design optimal treatment and to develop new strategies for identification and
      prevention of CVD in both the general population and families with FCH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>3-7 years</time_frame>
    <description>Fatal and non-fatal cardiovascular events will be evaluated by questionnaire and validated using hospital records and records from general practitioners.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1960</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>community-based cohort</arm_group_label>
    <description>The present study is a substudy in the Nijmegen Biomedical Study (NBS). The NBS is a prospective population survey aimed at investigating the frequency of genetic variations in the general population. The study population is recruited as a sex- and age-stratified random sample of all inhabitants of Nijmegen 20 to 90 years old (n=10.000). Recruitment has started in october 2001.
In the current study 1517 participants aged 50-70 years were included from 2005 to 2008, from whom baseline characteristics were obtained. All visited our hospital and during the visit venous blood was drawn, height and weight were measured, a questionnaire about medical history, life style habits, and family history was completed and non-invasive measurements of atherosclerosis were performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Familial Combined Hyperlipidemia</arm_group_label>
    <description>FCH is the most common inherited dyslipidemia in man. Affected individuals are characterized by elevated cholesterol and/or triglyceride levels and an increased risk of CVD. Our data base contains a unique population of 40 well-characterized FCH families, including 687 patients, relatives and spouses. These families were recruited in 1994 and extensively studied, including information on an extensive panel of biochemical and genetic parameters. In total 343 participants were included in the NIMA study; 103 FCH patients and 240 unaffected relatives from whom baseline characteristics were obtained.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants recruited from a population-based survey aged 50-70 years. Participants from
        families with Familial Combined Hyperlipidemia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Population-based cohort:

        Inclusion Criteria:

          -  aged 50-70 years at inclusion

        Exclusion Criteria:

          -  recent symptomatic CV disease (&lt;6 months)

        Familial Combined Hyperlipidemia:

        Inclusion Criteria:

          -  age &gt;18 years

        Exclusion Criteria:

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacqueline de Graaf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University Nijmegen Medical Centre, Dept. of General Internal Medicine, Division of Vascular Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anton FH Stalenhoef, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Nijmegen Medical Centre, Dept. of General Internal Medicine, Division of Vascular Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin den Heijer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Nijmegen Medical Centre, Dept. of Epidemiology and Biostatistics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzanne Holewijn, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Nijmegen Medical Centre, Dept. of General Internal Medicine, Division of Vascular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre, Department of General Internal Medicine, Division of Vascular Medicine</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de Vries JP, Kranendonk SE, Zeebregts CJ, van Sterkenburg SM, Geelkerken RH, van Rij AM, Williams MJ, Boll AP, Kostic JP, Jonasdottir A, Jonasdottir A, Walters GB, Masson G, Sulem P, Saemundsdottir J, Mouy M, Magnusson KP, Tromp G, Elmore JR, Sakalihasan N, Limet R, Defraigne JO, Ferrell RE, Ronkainen A, Ruigrok YM, Wijmenga C, Grobbee DE, Shah SH, Granger CB, Quyyumi AA, Vaccarino V, Patel RS, Zafari AM, Levey AI, Austin H, Girelli D, Pignatti PF, Olivieri O, Martinelli N, Malerba G, Trabetti E, Becker LC, Becker DM, Reilly MP, Rader DJ, Mueller T, Dieplinger B, Haltmayer M, Urbonavicius S, Lindblad B, Gottsäter A, Gaetani E, Pola R, Wells P, Rodger M, Forgie M, Langlois N, Corral J, Vicente V, Fontcuberta J, España F, Grarup N, Jørgensen T, Witte DR, Hansen T, Pedersen O, Aben KK, de Graaf J, Holewijn S, Folkersen L, Franco-Cereceda A, Eriksson P, Collier DA, Stefansson H, Steinthorsdottir V, Rafnar T, Valdimarsson EM, Magnadottir HB, Sveinbjornsdottir S, Olafsson I, Magnusson MK, Palmason R, Haraldsdottir V, Andersen K, Onundarson PT, Thorgeirsson G, Kiemeney LA, Powell JT, Carey DJ, Kuivaniemi H, Lindholt JS, Jones GT, Kong A, Blankensteijn JD, Matthiasson SE, Thorsteinsdottir U, Stefansson K. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat Genet. 2010 Aug;42(8):692-7. doi: 10.1038/ng.622. Epub 2010 Jul 11.</citation>
    <PMID>20622881</PMID>
  </reference>
  <results_reference>
    <citation>ter Avest E, Holewijn S, Stalenhoef AF, de Graaf J. Variation in non-invasive measurements of vascular function in healthy volunteers during daytime. Clin Sci (Lond). 2005 May;108(5):425-31.</citation>
    <PMID>15636580</PMID>
  </results_reference>
  <results_reference>
    <citation>ter Avest E, Abbink EJ, Holewijn S, de Graaf J, Tack CJ, Stalenhoef AF. Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Curr Med Res Opin. 2005 Sep;21(9):1469-76.</citation>
    <PMID>16197666</PMID>
  </results_reference>
  <results_reference>
    <citation>ter Avest E, Holewijn S, Bredie SJ, Stalenhoef AF, de Graaf J. Remnant particles are the major determinant of an increased intima media thickness in patients with familial combined hyperlipidemia (FCH). Atherosclerosis. 2007 Mar;191(1):220-6. Epub 2006 May 4.</citation>
    <PMID>16677651</PMID>
  </results_reference>
  <results_reference>
    <citation>ter Avest E, Holewijn S, Bredie SJ, van Tits LJ, Stalenhoef AF, de Graaf J. Pulse wave velocity in familial combined hyperlipidemia. Am J Hypertens. 2007 Mar;20(3):263-9.</citation>
    <PMID>17324737</PMID>
  </results_reference>
  <results_reference>
    <citation>Ter Avest E, Holewijn S, van Tits LJ, de Wit HM, Stalenhoef AF, de Graaf J. Endothelial function in familial combined hyperlipidaemia. Eur J Clin Invest. 2007 May;37(5):381-9.</citation>
    <PMID>17461984</PMID>
  </results_reference>
  <results_reference>
    <citation>Koenen TB, van Tits LJ, Holewijn S, Lemmers HL, den Heijer M, Stalenhoef AF, de Graaf J. Adiponectin multimer distribution in patients with familial combined hyperlipidemia. Biochem Biophys Res Commun. 2008 Nov 7;376(1):164-8. doi: 10.1016/j.bbrc.2008.08.111. Epub 2008 Aug 30.</citation>
    <PMID>18762168</PMID>
  </results_reference>
  <results_reference>
    <citation>Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis. J Clin Endocrinol Metab. 2009 Aug;94(8):2893-9. doi: 10.1210/jc.2009-0084. Epub 2009 May 5.</citation>
    <PMID>19417041</PMID>
  </results_reference>
  <results_reference>
    <citation>Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Brachial artery diameter is related to cardiovascular risk factors and intima-media thickness. Eur J Clin Invest. 2009 Jul;39(7):554-60. doi: 10.1111/j.1365-2362.2009.02152.x. Epub 2009 May 8.</citation>
    <PMID>19453648</PMID>
  </results_reference>
  <results_reference>
    <citation>Holewijn S, den Heijer M, van Tits LJ, Swinkels DW, Stalenhoef AF, de Graaf J. Impact of waist circumference versus adiponectin level on subclinical atherosclerosis: a cross-sectional analysis in a sample from the general population. J Intern Med. 2010 Jun;267(6):588-98. doi: 10.1111/j.1365-2796.2009.02192.x. Epub 2009 Nov 4.</citation>
    <PMID>20210840</PMID>
  </results_reference>
  <results_reference>
    <citation>Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Apolipoprotein B, non-HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk. J Intern Med. 2010 Dec;268(6):567-77. doi: 10.1111/j.1365-2796.2010.02277.x.</citation>
    <PMID>21091808</PMID>
  </results_reference>
  <results_reference>
    <citation>Holewijn S, Sniderman AD, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study. Eur J Clin Invest. 2011 Apr;41(4):423-33. doi: 10.1111/j.1365-2362.2010.02426.x. Epub 2010 Dec 3.</citation>
    <PMID>21128932</PMID>
  </results_reference>
  <results_reference>
    <citation>Bus BA, Marijnissen RM, Holewijn S, Franke B, Purandare N, de Graaf J, den Heijer M, Buitelaar JK, Voshaar RC. Depressive symptom clusters are differentially associated with atherosclerotic disease. Psychol Med. 2011 Jul;41(7):1419-28. doi: 10.1017/S0033291710002151. Epub 2010 Dec 10.</citation>
    <PMID>21144110</PMID>
  </results_reference>
  <results_reference>
    <citation>Holewijn S, den Heijer M, Stalenhoef AF, de Graaf J. Non-invasive measurements of atherosclerosis (NIMA): current evidence and future perspectives. Neth J Med. 2010 Dec;68(12):388-99. Review.</citation>
    <PMID>21209464</PMID>
  </results_reference>
  <results_reference>
    <citation>Marijnissen RM, Bus BA, Holewijn S, Franke B, Purandare N, de Graaf J, den Heijer M, Buitelaar JK, Oude Voshaar RC. Depressive symptom clusters are differentially associated with general and visceral obesity. J Am Geriatr Soc. 2011 Jan;59(1):67-72. doi: 10.1111/j.1532-5415.2010.03228.x.</citation>
    <PMID>21226677</PMID>
  </results_reference>
  <results_reference>
    <citation>Ter Avest E, Stalenhoef AF, de Graaf J. What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction? Clin Sci (Lond). 2007 May;112(10):507-16. Review.</citation>
    <PMID>17419684</PMID>
  </results_reference>
  <results_reference>
    <citation>de Graaf J, van der Vleuten GM, ter Avest E, Dallinga-Thie GM, Stalenhoef AF. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. J Clin Endocrinol Metab. 2007 Apr;92(4):1269-75. Epub 2007 Jan 16.</citation>
    <PMID>17227806</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Vleuten GM, Isaacs A, Zeng WW, ter Avest E, Talmud PJ, Dallinga-Thie GM, van Duijn CM, Stalenhoef AF, de Graaf J. Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia. Biochim Biophys Acta. 2007 Jan;1772(1):81-8. Epub 2006 Oct 26.</citation>
    <PMID>17157483</PMID>
  </results_reference>
  <results_reference>
    <citation>ter Avest E, Abbink EJ, de Graaf J, Tack CJ, Stalenhoef AF. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest. 2005 Sep;35(9):558-64.</citation>
    <PMID>16128862</PMID>
  </results_reference>
  <results_reference>
    <citation>Brouwers MC, de Graaf J, van Greevenbroek MM, Georgieva AM, van der Kallen CJ, Ter Avest E, Stehouwer CD, Stalenhoef AF, de Bruin TW. Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained? Clin Sci (Lond). 2008 Mar;114(5):393-401.</citation>
    <PMID>17953518</PMID>
  </results_reference>
  <results_reference>
    <citation>van Himbergen TM, van Tits LJ, Ter Avest E, Roest M, Voorbij HA, de Graaf J, Stalenhoef AF. Paraoxonase (PON1) is associated with familial combined hyperlipidemia. Atherosclerosis. 2008 Jul;199(1):87-94. Epub 2007 Dec 21.</citation>
    <PMID>18096166</PMID>
  </results_reference>
  <results_reference>
    <citation>Murabito JM, White CC, Kavousi M, Sun YV, Feitosa MF, Nambi V, Lamina C, Schillert A, Coassin S, Bis JC, Broer L, Crawford DC, Franceschini N, Frikke-Schmidt R, Haun M, Holewijn S, Huffman JE, Hwang SJ, Kiechl S, Kollerits B, Montasser ME, Nolte IM, Rudock ME, Senft A, Teumer A, van der Harst P, Vitart V, Waite LL, Wood AR, Wassel CL, Absher DM, Allison MA, Amin N, Arnold A, Asselbergs FW, Aulchenko Y, Bandinelli S, Barbalic M, Boban M, Brown-Gentry K, Couper DJ, Criqui MH, Dehghan A, den Heijer M, Dieplinger B, Ding J, Dörr M, Espinola-Klein C, Felix SB, Ferrucci L, Folsom AR, Fraedrich G, Gibson Q, Goodloe R, Gunjaca G, Haltmayer M, Heiss G, Hofman A, Kieback A, Kiemeney LA, Kolcic I, Kullo IJ, Kritchevsky SB, Lackner KJ, Li X, Lieb W, Lohman K, Meisinger C, Melzer D, Mohler ER 3rd, Mudnic I, Mueller T, Navis G, Oberhollenzer F, Olin JW, O'Connell J, O'Donnell CJ, Palmas W, Penninx BW, Petersmann A, Polasek O, Psaty BM, Rantner B, Rice K, Rivadeneira F, Rotter JI, Seldenrijk A, Stadler M, Summerer M, Tanaka T, Tybjaerg-Hansen A, Uitterlinden AG, van Gilst WH, Vermeulen SH, Wild SH, Wild PS, Willeit J, Zeller T, Zemunik T, Zgaga L, Assimes TL, Blankenberg S, Boerwinkle E, Campbell H, Cooke JP, de Graaf J, Herrington D, Kardia SL, Mitchell BD, Murray A, Münzel T, Newman AB, Oostra BA, Rudan I, Shuldiner AR, Snieder H, van Duijn CM, Völker U, Wright AF, Wichmann HE, Wilson JF, Witteman JC, Liu Y, Hayward C, Borecki IB, Ziegler A, North KE, Cupples LA, Kronenberg F. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet. 2012 Feb 1;5(1):100-12. doi: 10.1161/CIRCGENETICS.111.961292. Epub 2011 Dec 23.</citation>
    <PMID>22199011</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2012</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Radboud University</investigator_affiliation>
    <investigator_full_name>Jacqueline de Graaf</investigator_full_name>
    <investigator_title>Prof. Dr. J. de Graaf</investigator_title>
  </responsible_party>
  <keyword>(subclinical)atherosclerosis</keyword>
  <keyword>non-invasive measurements</keyword>
  <keyword>intima-media thickness</keyword>
  <keyword>flow-mediated dilation</keyword>
  <keyword>pulse wave velocity and analysis</keyword>
  <keyword>fatal and non-fatal cardiovascular events</keyword>
  <keyword>ankle-brachial index (at rest and after exercise)</keyword>
  <keyword>general population</keyword>
  <keyword>Familial Combined Hyperlipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

